Also known as LY3437943
Investigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
Retatrutide is an Eli Lilly–developed triple agonist targeting GIP, GLP-1, and glucagon receptors. Phase 2 trials reported ~24% mean weight reduction at 48 weeks at the highest dose.
Retatrutide (development code LY3437943) is an investigational single peptide that activates three receptors — GIP, GLP-1, and glucagon. Adding glucagon-receptor agonism to the incretin pair is studied as a way to increase energy expenditure and lipolysis on top of the insulinotropic and satiety effects of GIP and GLP-1.
Developed by Eli Lilly, it remains investigational and has not been approved. Phase 2 results reported notably large mean weight reductions at the highest doses over roughly a year, placing it among the most closely watched "triple agonist" candidates in late-stage metabolic research.
GIP + GLP-1 (insulinotropic, satiety) plus glucagon (energy expenditure, lipolysis).
Behind every vial of Retatrutide is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Retatrutide, specifically, is brought into being.
On paper, Retatrutide is C221H342N46O68 — about 4,731.5 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Retatrutide is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.
The crude mixture — Retatrutide plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Retatrutide proves itself: identity confirmed by mass spectrometry against its ~4,731.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Retatrutide — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Retatrutide to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Retatrutide is an investigational triple agonist targeting the GIP, GLP-1, and glucagon receptors, studied in late-stage trials for obesity and type 2 diabetes.
It adds glucagon-receptor activation — studied for increased energy expenditure and fat breakdown — to the insulinotropic and satiety effects of GIP and GLP-1.
No. It is investigational and has not received FDA approval; all data comes from clinical research.
Eli Lilly. This page is a research and educational reference, not medical advice or an offer for sale.